ACIU
Strong SellSinkerAC Immune SA · Healthcare · Switzerland · $299M · Avg Vol: $535K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT AC IMMUNE SA
Read
AC Immune SA is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing precision medicines and diagnostics for neurodegenerative diseases, focusing on conditions like Alzheimer's and Parkinson's. The company leverages proprietary technology platforms like Morphomer and SupraAntigen to target misfolded proteins, a key pathological hallmark of these diseases. AC Immune's competitive edge is its specialized R&D in this complex field, aiming to bring innovative solutions to areas of high unmet medical need.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.8M | 18.0M | 33.2M | 4.3M | -3.2% | 21.2M | 44.1M | 106.7M | 395.6% |
| EPS | -1.03 | -0.78 | -0.62 | -0.85 | — | -0.53 | -0.50 | 0.60 | — |
| Shares | 83.6M | 99.2M | 100.4M | 101.7M | +21.7% | 99.4M | — | — | — |
| Debt | 3.4M | 4.3M | 6.6M | 5.5M | 17.5% | 5.0M | — | — | — |
| Equity | 205.5M | 195.4M | 136.5M | 54.6M | -35.7% | — | — | — | — |
| Op CF | -89.5M | -73.5M | 80.1M | -84.2M | — | -61.2M | — | — | — |
| Inv CF | 28.9M | 79.8M | -128.1M | 77.3M | — | — | — | — | — |
| Fin CF | -1.6M | 52.6M | -1.4M | -1.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ACIU are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ACIU | AC Immune SA(you) | $299M | 12 | Strong Sell |
| SANN.SW | Santhera Pharmaceuticals Holding AG | $290M | 20 | Sell |
| MOLN | Molecular Partners AG | $172M | 19 | Strong Sell |
| OCS | Oculis Holding AG | $678M | 6 | Strong Sell |
| MLTX | MoonLake Immunotherapeutics | $1.3B | 8 | Strong Sell |
| IDIA.SW | Idorsia Ltd | $1.7B | 21 | Sell |
| PHVS | Pharvaris N.V. | $2.5B | 21 | Sell |
| CRSPN.MX | CRISPR Therapeutics AG | $5.6B | 20 | Strong Sell |
| BANB.SW | Bachem Holding AG | $7.1B | 53 | Hold |
| BSLN.SW | Basilea Pharmaceutica AG | $986M | 98 | Strong Buy |
Peer medians: ROE 11.1% · P/E 29.9x · Gross margin 62.5%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.